TRT Guidelines Data: 10 Current Guidance Sets Compared (2026)

By TRT Provider Guide
Published and last verified: September 2, 2026 · Dataset version 2.0 · Not clinically reviewed

TRT guidelines can give very different readings of the same lab result. In this September 2, 2026 audit, a morning total testosterone result of 320 ng/dL falls below the main action line in 3 guidance sets, lands in a gray or context zone in 3, sits above the main numeric line in 3, and has no FDA diagnostic cutoff to compare with.

“Symptoms alone are not diagnostic of hypogonadism.”
— Endocrine Society, July 16, 2026

The number to quote: At 320 ng/dL, the ten current guidance sets in this audit split 3 below the main line, 3 gray or context-dependent, 3 above the main line, and 1 with no diagnostic cutoff.

That split is original analysis from the TRT Guideline Comparison Dataset, 2026. It does not mean three groups would automatically prescribe testosterone. Every current clinical document in the comparison also asks about symptoms, repeat testing, causes, safety, and treatment goals.

Source: TRT Provider Guide, TRT Guideline Comparison Dataset, 2026, version 2.0. The eight-document denominator is AUA, Endocrine Society, EAU, EAA, BSSM, Society for Endocrinology, CUA, and ICSM 2024. FDA regulatory labeling and Alabama Board guidance are shown separately because they are not professional-society clinical guidelines.

Figure 1 source: TRT Provider Guide application of each issuing body's published threshold or interpretation band to 320 ng/dL; verified September 2, 2026. Download the underlying comparison data (CSV).

Data files: one-fact-per-row comparison dataset (CSV) · guideline and regulatory timeline (CSV) · 320 ng/dL verdict chart (SVG) · threshold comparison chart (SVG)

Scope in plain words. TRT means prescription testosterone used to treat a diagnosed testosterone deficiency. The source documents do not all use hypogonadism, testosterone deficiency, and low testosterone in exactly the same way. This page keeps each body's wording and does not treat those labels as perfect synonyms. It describes published guidance. It does not diagnose anyone or tell any person to start, stop, or change treatment.

TRT guidelines in 2026: the 10 guidance sets in this audit

There is no single worldwide TRT rulebook. This audit compares eight current professional-group clinical documents, one federal regulatory track, and one state medical-board guidance document.

The categories matter:

• A clinical guideline or consensus recommendation tells clinicians how an issuing group reads the evidence.
• An FDA label states approved uses, warnings, and product instructions. It is not a full diagnostic guideline.
• The Alabama document is titled Recommended Guidelines. It is board guidance, not a national standard and not labeled as a statute or regulation.

Source: issuing-body documents: AUA, Endocrine Society, EAU, EAA, BSSM, Society for Endocrinology, CUA, ICSM 2024, FDA, and Alabama Board of Medical Examiners. Verified September 2, 2026.

Why the main denominator is eight

The cross-guideline counts use only the eight current professional-group clinical documents. That keeps like with like.

The FDA is outside that denominator because product labels are not a complete clinical workup. Alabama is outside it because it is one state board's recommended guidance. The inactive American College of Physicians guideline is outside it because ACP now lists that 2020 document as inactive and because it covered a narrow question: whether to treat age-related low testosterone, not how to diagnose all male hypogonadism.

TRT guideline statistics: what the eight clinical documents agree on

The numbers differ. The process is much more stable.

All eight current clinical documents require both sides of the diagnosis: clinical features and biochemical evidence. A low lab result without the right clinical setting is not the whole diagnosis. Symptoms without low and confirmed testosterone are not the whole diagnosis either.

Source: TRT Provider Guide normalization of the eight issuing-body documents listed under Table 2, using the definitions in the Methodology section. Verified September 2, 2026.

The biggest shared lesson is simple: the diagnosis is a sequence, not a number. The usual sequence is symptoms or signs, a properly timed total testosterone test, confirmation, a search for the cause, a safety review, a fertility discussion, and a plan to measure response and harm.

Low testosterone cutoff data: why 264 and 346 are 31% apart

The lowest prominent number in the current documents is 264 ng/dL. The highest common main line is 12 nmol/L, equal to 346 ng/dL with the conversion used in this dataset.

The gap is 82 ng/dL, or 31.1% of 264.

That comparison is useful, but the two numbers are not the same kind of rule:

• 264 ng/dL is the Endocrine Society guideline's harmonized lower limit of the reference range for healthy, non-obese young men when a CDC-standardized assay is used. The recommendation itself does not turn 264 into a universal hard diagnostic cutoff.
• 12 nmol/L is used by EAU as a reliable diagnostic threshold and by ICSM as a reliable threshold. BSSM uses the same line in its treatment statements. EAA and the SfE/ACB statement use 12 as the top of a gray band: values above it make hypogonadism unlikely in the usual setting.

So the honest sentence is not “the guidelines disagree between two hard cutoffs.” It is: prominent decision numbers run from a 264 ng/dL harmonized reference limit to a 346 ng/dL clinical threshold, a 31.1% spread.

Source: diagnostic recommendations and interpretation statements in the primary documents linked under Table 2. Conversion: testosterone ng/dL = nmol/L × 28.84. Values are rounded to the nearest whole ng/dL.

Figure 2 source: TRT Provider Guide normalization of values as published by the issuing bodies; verified September 2, 2026. The figure labels 264 as a reference limit, not a hard Endocrine Society cutoff.

A lab range is not a diagnosis by itself. Assays can differ. Time of day matters. Food can matter under several documents. Illness can lower a result. Sex hormone–binding globulin, called SHBG, can make total testosterone harder to read. For age-based reference context, see Testosterone Levels by Age.

What happens to a 320 ng/dL testosterone result?

A total testosterone result of 320 ng/dL equals about 11.1 nmol/L. It was chosen because it sits above the AUA and Alabama 300 lines but below the 12 nmol/L line used by several European, UK, and international documents.

This is not a treatment recommendation. It is a controlled comparison: one morning result, ten published frameworks.

Source: TRT Provider Guide application of the published numbers and interpretation bands in Table 4 to 320 ng/dL; verified September 2, 2026. Categories describe the number only. They do not predict a final diagnosis or prescription.

The result is 3 below, 3 gray, 3 above, 1 no cutoff. That is why a clean report should always name the document and the rule being used. “The guidelines say 320 is low” is not accurate. “EAU places 320 below its 12 nmol/L line” is accurate.

What tests do TRT guidelines require before treatment?

Total testosterone is the starting test. The details are where errors happen.

Source: diagnostic testing sections of AUA, Endocrine Society, EAU, EAA, BSSM, SfE/ACB, CUA, and ICSM 2024. Verified September 2, 2026.

Why two morning tests are common

Testosterone changes during the day. It can also shift with sleep, food, acute illness, medicines, obesity, and lab method. Repeat testing lowers the chance that one unusual morning becomes a lifelong label.

The Endocrine Society's July 2026 statement made the point in beginner-friendly terms: diagnosis should rest on at least two early-morning, fasting tests plus the clinical picture. The Society also warned that non-standardized assays can read the same sample differently.

What else gets checked before treatment

The exact workup depends on the person and the source document. Common pieces include:

• LH and sometimes FSH: These hormones help separate a testicular cause from a brain or pituitary cause.
• Prolactin: This can help find a pituitary problem, especially when testosterone and LH are low.
• SHBG and calculated free testosterone: These help when total testosterone is borderline or SHBG is likely to be unusual.
• Hemoglobin and hematocrit: Testosterone can raise red-cell measures, so a high baseline matters.
• PSA and prostate assessment: The age, risk rules, and follow-up differ by document.
• Fertility plans: Standard systemic testosterone can reduce sperm production.
• Medicines, illness, sleep, weight, and substance use: These can lower testosterone or change treatment risk.

No single table can replace the cause workup. A very low result with low or normal LH raises a different question than a borderline result in a man who slept poorly, was acutely ill, or takes a medicine known to affect the hormone axis.

TRT monitoring schedule data: when do labs get rechecked?

There is no one first-recheck date for every product. Gels, short-acting injections, long-acting injections, patches, oral products, pellets, and nasal products reach and hold levels differently.

Source: follow-up tables and treatment sections in the issuing-body documents. Alabama details come from its Recommended Guidelines, approved February 20, 2025. FDA labeling is product-specific; the class-wide regulatory page does not create one universal schedule. Verified September 2, 2026.

When do guidelines say to stop if symptoms do not improve?

The answer is not one fixed date.

• AUA: Discuss stopping after 3–6 months when testosterone has normalized but the target symptoms have not improved.
• Alabama guidance: At the 3-month review, offer discontinuation if no benefit is confirmed.
• BSSM: It gives symptom-specific response windows and supports stopping when an adequate trial produces no meaningful benefit.
• ACP 2020, now inactive: For its narrow age-related-low-testosterone question, it called for reevaluation within 12 months and stopping when sexual function did not improve.

A lab number can reach a target while the reason for treatment does not change. The current documents generally treat that as a reason to recheck the diagnosis, dose, formulation, adherence, competing causes, and whether treatment should continue.

What hematocrit is too high on TRT?

Hematocrit is the share of blood made up of red blood cells. Testosterone can raise it. A very high value may lead to a lower dose, a different product, a pause, further testing, or removal of blood under medical care.

Six of the eight current clinical documents use 54% as their main ceiling or action point. CUA uses 55%. Society for Endocrinology begins action above 50% and calls for stopping and urgent hematology review when the rise is marked.

Source: hematocrit and safety sections in the eight primary clinical documents listed under Table 6. Wording such as “above,” “at least,” and “markedly raised” is kept because the comparators are not identical. Verified September 2, 2026.

The safe takeaway is not “54 is always fine.” Baseline matters. The rate of rise matters. Smoking, sleep apnea, lung disease, altitude, dehydration, and the testosterone formulation can matter. EAU tells clinicians to watch people at high risk more often. AUA tells them to explain a baseline value above 50% before moving ahead.

What testosterone level should TRT aim for?

The documents do not agree on one “optimal” target. They do agree that the goal is not an above-normal level.

Source: treatment-target sections of the issuing-body documents. Alabama's 700 and 800 values apply to its injection guidance and are not a universal target for all products. Verified September 2, 2026.

The old draft claimed that 450–490 ng/dL was the one band inside every target. That cannot be supported. EAU does not publish a fixed numeric target, and its discussion of the Testosterone Trials' 280–873 ng/dL range describes a study approach, not an EAU target. Some documents use words such as mid-normal instead of a fixed band. A mathematical overlap across unlike targets would create false precision.

What do TRT guidelines say about PSA and the prostate?

The documents do not share one PSA rule for every age and risk group. A clean summary has to name the body.

Source: prostate sections of the AUA guideline, Endocrine Society guideline, EAU 2026 guideline, and Alabama recommended guidelines. Verified September 2, 2026.

A rising PSA is not the same thing as a prostate-cancer diagnosis. It is a signal to confirm the result and decide whether further evaluation is needed. The exact step depends on age, baseline PSA, rate of change, exam, symptoms, personal history, family history, and the prostate guideline used in that country.

Who should not start TRT under current guidance?

There is no honest one-line list that fits every document. The wording and strength differ.

The clearest repeated barriers are:

• a near-term plan to conceive or an active desire for fertility;
• a high or unexplained hematocrit;
• active or untreated prostate or male breast cancer in documents that address it;
• certain recent cardiovascular events, uncontrolled heart failure, severe untreated sleep apnea, severe urinary symptoms, or high prostate risk, depending on the document;
• no confirmed biochemical deficiency or no matching clinical picture.

Source: contraindication and safety sections of the issuing-body documents. This table preserves differences rather than turning them into a claim that every body uses the same list. Verified September 2, 2026.

A person can also have a reason for low testosterone that should be treated first. Examples include a pituitary problem, hyperprolactinemia, severe obesity, acute illness, untreated sleep problems, or a medicine effect. Several guidelines tell clinicians to look for and treat reversible causes before or alongside testosterone decisions.

What do TRT guidelines say about fertility?

All eight current clinical documents address fertility or sperm suppression. None treats standard systemic testosterone as fertility-neutral.

Testosterone from outside the body can turn down LH and FSH signals from the brain. That can lower sperm production. Testicular size can fall. Recovery after stopping can take time and is not identical for every man.

Source: fertility recommendations in the eight primary clinical documents. ICSM also reviews small studies of short-acting intranasal testosterone, but that discussion is not a recommendation that standard testosterone therapy preserves fertility. Verified September 2, 2026.

The practical question comes before the prescription: Could this person want children now or later? The answer can change the drug choice and whether a fertility specialist should be involved.

What current TRT guidelines do not support

The documents are not identical, but none supports a shortcut built from one vague symptom and one random blood draw.

They do not support one universal cutoff

AUA uses 300 ng/dL. CUA uses 10 nmol/L as a reasonable but non-absolute threshold. EAU and ICSM use 12 nmol/L. EAA and SfE use bands. Endocrine Society uses a reference limit plus clinical and assay context.

They do not support an above-normal treatment goal

Targets are mid-normal, middle-tertile, normal, or formulation-specific. No current clinical document in this audit sets an above-normal level as the routine goal.

They do not all promise more energy or sharper thinking

The evidence and wording differ:

• AUA says evidence is inconclusive for energy, fatigue, and cognition.
• EAU says not to use testosterone to improve cognition, vitality, or physical strength in aging men.
• The inactive ACP guideline said not to start testosterone for energy, vitality, physical function, or cognition in men with age-related low testosterone.

They do not all handle a “normal” total result the same way

EAU and ICSM explicitly say not to use testosterone in eugonadal men. CUA, however, allows a supervised three-month trial in selected symptomatic men with an equivocal picture and a total testosterone result that appears normal, with weak recommendation strength and low-quality evidence. That is an exception built around uncertainty, not a blank check for treatment at any number.

They do not replace the current product label

A clinical guideline may say when treatment is reasonable. The FDA-approved label for the exact gel, injection, patch, oral product, pellet, buccal system, or nasal product controls that product's approved use, warnings, dosing, and lab timing.

What changed in TRT guidance in 2025 and 2026?

The largest recent changes are regulatory and publication updates, not a new universal diagnostic number.

Source: FDA February 2025 action, FDA Testosterone Information, Federal Register notice, Alabama guidance, ICSM article, Endocrine Society statement, and EAU 2026 chapter. Verified September 2, 2026.

The FDA sequence is easy to misstate. In February 2025, FDA said to retain the age-related limitation. In June 2026, FDA requested removal of it. A page that reports only one of those dates can give the wrong current picture.

Historical note: the ACP 2020 guideline is inactive

The American College of Physicians issued a 2020 guideline on testosterone treatment in adult men with age-related low testosterone. It did not set a diagnostic cutoff. It focused on whether treatment improved outcomes after age-related low testosterone was already identified.

ACP now places that guideline on its Inactive ACP Guidelines page. For that reason, it is not counted as one of the ten current guidance sets and is not used in the eight-document clinical denominator.

Its narrow historical message is still useful to understand old articles: discuss treatment mainly for sexual dysfunction, reevaluate benefit, and do not start it for energy, vitality, physical function, or cognition alone. But calling ACP 2020 a current broad TRT guideline in 2026 would be wrong.

Source: ACP's inactive-guidelines list and the 2020 ACP guideline, checked September 2, 2026.

Do states have their own TRT guidelines?

This audit verified one clear state-board example: Alabama.

Alabama's document is titled Recommended Guidelines for Testosterone Replacement Therapy in Males. It calls for symptoms, two early-morning tests, a result below 300 ng/dL, a confirmatory fasting workup, a three-month review, six-month safety labs, and an annual in-person physician visit. It also says physicians should not refill testosterone without testosterone and hemoglobin/hematocrit safety labs from the prior six months.

Those are specific Alabama Board recommendations. This page does not claim that every Alabama sentence is a statute, that every state uses the same rules, or that states without a similar document have no legal requirements. A complete state-law answer would require a separate, current 50-state legal review of statutes, board rules, controlled-substance requirements, telemedicine law, prescribing standards, and enforcement materials.

Source: Alabama Board of Medical Examiners Recommended Guidelines, approved February 20, 2025.

Methodology: how the TRT Guideline Comparison Dataset was made

This section is the audit trail. It explains exactly what was counted and what was not.

Research question

The dataset asks: How do current, broad guidance documents for adult male testosterone deficiency differ on diagnosis, testing, treatment targets, safety, and monitoring as of September 2, 2026?

Inclusion rules

A current clinical document was included in the main denominator when it:

1. came from a professional medical body;
2. covered broad adult male testosterone-deficiency or hypogonadism care rather than one drug, one cancer-survivor group, or one narrow disease;
3. was the newest edition, validity-confirmed version, or current page available from that body on September 2, 2026; and
4. gave enough original recommendations to code the main decision points.

The eight documents meeting those rules were AUA, Endocrine Society, EAU, EAA, BSSM, Society for Endocrinology, CUA, and ICSM 2024.

Separate guidance tracks

Two current documents were included in the reader-facing ten-set comparison but excluded from clinical-society denominators:

• FDA: class-wide regulatory actions and current federal testosterone information;
• Alabama Board of Medical Examiners: state recommended guidance.

The ACP 2020 guideline was kept only in the historical table because ACP lists it as inactive.

Document pairing rule

The Society for Endocrinology's 2022 clinical guideline and the 2023 joint SfE/ACB biochemical position statement were treated as one clinical guidance set, not two votes. The 2022 document covers treatment and monitoring. The 2023 statement adds laboratory interpretation. Counting them separately would give one organization extra weight.

Unit conversion

The dataset uses:

ng/dL = nmol/L × 28.84

The factor comes from testosterone's molecular weight of about 288.4 g/mol. Converted ng/dL values are rounded to the nearest whole number in reader tables. Source values stay in their published units in the CSV.

Examples:

• 8 nmol/L = 230.7 ng/dL, shown as 231;
• 10 nmol/L = 288.4 ng/dL, shown as 288;
• 12 nmol/L = 346.1 ng/dL, shown as 346.

Some papers print 12 nmol/L as 350 ng/dL. The dataset preserves the printed value and also records the formula conversion.

Counting rules

• Symptoms plus biochemical evidence: counted yes only when the document joins the clinical picture to low or deficient testosterone evidence.
• Repeat testing: counted explicit only when the document calls for repeat, consecutive, consistently low, or at least two measurements.
• One result enough: counted yes only if a document plainly says one result can complete diagnosis. None did.
• Fasting required: counted yes when fasting is part of the recommendation, not merely discussed.
• Hematocrit 54%: counted yes when 54% is the main ceiling, stop point, or intervention point. CUA's 55% and SfE's different action scheme were kept separate.
• Fertility: counted addressed when the document warns about sperm suppression, advises against treatment while trying to conceive, or changes treatment to preserve fertility.
• Above-normal target: counted yes only if routine treatment is aimed above the normal or physiologic range. None did.

The 320 ng/dL experiment

The 320 analysis holds the lab value constant and applies each set's published total-testosterone number or band:

• Below main line: 320 falls under a primary published line used to support diagnosis or treatment consideration.
• Gray or context-dependent: 320 falls inside a published borderline band or above a reference limit where free testosterone, SHBG, assay, and clinical context can still change interpretation.
• Above main numeric line: 320 is above the document's primary numeric threshold.
• No diagnostic cutoff: the document publishes no universal total-testosterone number.

The categories do not say whether a person would receive treatment. They isolate one decision point so the disagreement can be measured.

Verification process

Each included fact was checked against the issuing body's guideline page, the original paper, an official regulator page, or the original board document. Secondary summaries were not used to override a primary source. The dataset records one source URL and the verification date for each row.

Versioning

Version 2.0 replaces the draft's mixed denominator. It:

• adds the full Society for Endocrinology clinical guideline to the clinical set;
• pairs it with the SfE/ACB lab statement;
• separates FDA and Alabama from clinical-society counts;
• moves inactive ACP to history;
• changes the 320 table from 11 rows to the promised 10 current sets;
• removes claims that could not be reproduced from like-for-like targets.

Limits of this dataset

This comparison is broad, but it has edges.

1. It is a document audit, not a patient-outcome study.
2. It compares issuing-body wording. It does not measure how every clinician practices.
3. AUA, Endocrine Society, EAA, BSSM, SfE, CUA, and ICSM do not all update on the same schedule.
4. The EAU page is updated annually, so its year changes more often than most other documents.
5. FDA-approved testosterone products have different labels. A class-wide FDA row cannot replace the current label for a specific product.
6. Alabama is one verified state example. This is not a 50-state legal survey.
7. Total testosterone thresholds are not interchangeable with free-testosterone thresholds, assay reference ranges, or treatment targets.
8. The 320 ng/dL split is a reproducible reading of published rules, not proof that three clinicians would reach each final decision.
9. The page was not clinically reviewed. It should not be used for personal diagnosis or dosing.
10. A source can change after the verification date. The date is shown so later readers can repeat the check.

TRT guidelines FAQ

What testosterone level qualifies for TRT?

There is no one worldwide cutoff. AUA uses below 300 ng/dL as a reasonable line. CUA uses below 10 nmol/L, about 288 ng/dL, as reasonable but not absolute. EAU and ICSM use 12 nmol/L, about 346 ng/dL. Endocrine Society uses symptoms, consistently low results, assay context, and a 264 ng/dL harmonized lower reference limit rather than one universal hard cutoff.

Is 320 ng/dL low testosterone?

It depends on the guidance set and the rest of the case. In this audit, 320 ng/dL is below the main line in three sets, gray or context-dependent in three, above the main numeric line in three, and not classifiable by an FDA diagnostic cutoff.

Do you need two testosterone tests?

Seven of the eight current clinical documents explicitly call for repeat or consistently low testing. CUA calls for a morning test but does not print a fixed count in its main recommendation. None of the eight explicitly says one result alone is enough.

Should a testosterone test be fasting?

Five of the eight current clinical documents require fasting. BSSM advises an ideally fasted draw. AUA does not make fasting a diagnostic requirement. CUA does not specify fasting in its main testing recommendation.

What is the AUA cutoff for low testosterone?

The AUA says total testosterone below 300 ng/dL is a reasonable cutoff supporting diagnosis. It also requires symptoms or signs and at least two early-morning tests on separate days.

What is the Endocrine Society cutoff?

The Endocrine Society recommendation does not set one universal hard cutoff. Its 2018 guideline shows 264 ng/dL as a harmonized lower reference limit for CDC-certified assays. Its July 2026 statement refers to a common clinical threshold near 300 ng/dL while still requiring symptoms and at least two early-morning fasting tests.

What hematocrit is too high on TRT?

Six of the eight current clinical documents use 54% as the main ceiling or action point. CUA uses 55%. Society for Endocrinology starts action above 50% and escalates when the value is markedly raised. A high or rising result needs clinician review; it is not a self-treatment number.

How often should TRT blood work be done?

Most documents have an early review around three to six months and at least annual follow-up once stable. The exact testosterone draw depends on the product. EAU uses 3, 6, and 12 months, then yearly. CUA uses baseline, 3 months, 6 months, then yearly. AUA uses formulation-specific early timing and then testosterone every 6–12 months.

What is the target testosterone level on TRT?

There is no one target. AUA prints 450–600 ng/dL. CUA prints 14–17 nmol/L, about 404–490 ng/dL. BSSM prints 15–30 nmol/L, about 433–865 ng/dL. Several others say mid-normal or normal and adjust the draw to the product. None sets an above-normal routine goal.

Does TRT affect fertility?

Yes. All eight current clinical documents address fertility or sperm suppression. Standard systemic testosterone can lower LH and FSH signaling and reduce sperm production. Men who may want children should raise that before treatment.

Does the FDA have a TRT guideline?

FDA has product labels, safety communications, and regulatory actions. Those are not a complete clinical diagnostic guideline. FDA does not publish one universal testosterone cutoff for diagnosis.

Are there new TRT guidelines in 2026?

EAU has a 2026 annual edition, and Endocrine Society issued a July 2026 statement, but the Society's full clinical practice guideline remains the 2018 document. FDA also requested label updates in June 2026. These changes did not create one new worldwide cutoff.

Is the ACP 2020 testosterone guideline current?

No. ACP lists its 2020 age-related-low-testosterone guideline as inactive. It remains useful as historical context but is not counted as a current guideline here.

How to cite this page

This block gives neutral attribution details for readers who need a citation format.

Page citation

TRT Provider Guide. “TRT Guidelines Data: 10 Current Guidance Sets Compared (2026).” By TRT Provider Guide. Last verified September 2, 2026. https://trtproviderguide.com/research/trt-guidelines/

Dataset citation

TRT Provider Guide. TRT Guideline Comparison Dataset, 2026. Version 2.0. Verified September 2, 2026. https://trtproviderguide.com/research/data/trt-guidelines-dataset-2026.csv

Suggested description of the original 320 analysis

“TRT Provider Guide's September 2, 2026 comparison found that a 320 ng/dL morning total testosterone result fell below the main line in three current guidance sets, into a gray or context zone in three, above the main numeric line in three, and under no diagnostic cutoff in FDA labeling.”

Primary sources

Every major clinical, status, and regulatory claim above traces to an issuing body or original publication.

1. American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Published 2018; reviewed and validity confirmed 2024.
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. 2018.
3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018.
4. Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources.
5. Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026.
6. European Association of Urology. Sexual and Reproductive Health Guideline, Chapter 3: Male Hypogonadism. 2026 edition.
7. Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020.
8. Hackett G, Kirby M, Rees RW, et al. British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency. World Journal of Men's Health. 2023.
9. Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clinical Endocrinology. 2022.
10. Jayasena CN, de Silva NL, O'Reilly MW, et al. Standardising the biochemical confirmation of adult male hypogonadism: joint SfE/ACB position statement. Annals of Clinical Biochemistry. 2023.
11. Grober ED, Krakowsky Y, Khera M, et al. Canadian Urological Association guideline on testosterone deficiency in men. Canadian Urological Association Journal. 2021.
12. Khera M, Torres LO, Grober ED, et al. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. 2025.
13. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.
14. U.S. Food and Drug Administration. Testosterone Information. Content current June 23, 2026.
15. Federal Register. Potential New Indication for Testosterone Replacement Therapy. April 20, 2026.
16. Alabama Board of Medical Examiners. Recommended Guidelines for Testosterone Replacement Therapy in Males. Approved February 20, 2025.
17. American College of Physicians. Inactive ACP Guidelines.
18. Qaseem A, Horwitch CA, Vijan S, et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone. ACP clinical guideline. 2020.
19. National Library of Medicine, PubChem. Testosterone compound record, molecular weight 288.4.

Educational information only. This page reports published guidance and original document comparison. It is not medical advice and cannot decide whether testosterone therapy is right for any person.